Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • Analyst Insights & IR
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Alteogen (196170) Decides to Table Agenda for Delisting Approval to Relist on KOSPI Market

Posted on November 6, 2025July 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Alteogen (196170) Decides to Table Agenda for Delisting Approval to Relist on KOSPI Market

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-11-06

Disclosure Type: Decision to Table Agenda for Delisting Approval

💡 3-Second Summary

Alteogen’s board has decided to table a “KOSDAQ Delisting” agenda at the upcoming extraordinary general meeting of shareholders on December 8, which is a mandatory regulatory step to move its listing venue from KOSDAQ to the main KOSPI board.

📊 1. [Summary of Core Disclosure Content and Key Figures]

  • Purpose of Disclosure: To proceed with delisting from the KOSDAQ market and promote relocation to the KOSPI (Securities Market), conditional upon receiving listing approval from the KOSPI market.
  • EGM Date and Venue: The agenda will be submitted to the Extraordinary General Meeting of Shareholders on December 8, 2025, at 09:00 AM, held at the Daejeon Convention Center, 1st Floor, Medium Conference Room.
  • Board Decision Date: The board meeting was held on November 06, 2025, with two outside directors and an internal auditor in attendance.
  • Share Distribution Status (As of September 30, 2025):
    • Largest Shareholder (Park Soon-jae) & Associates: 10,891,700 shares (20.36%)
    • 5% or Greater Shareholder (Hyung In-woo): 2,700,000 shares (5.05%)
    • Other Shareholders: 39,914,088 shares (74.59%)
  • Conditions and Protections: This matter was resolved by the board and may change depending on the voting results at the EGM on December 8, 2025, and approvals from relevant regulatory authorities.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

While the term ‘Delisting’ may initially sound alarming, this disclosure represents a routine administrative prerequisite for moving to the KOSPI market. Since the KOSDAQ delisting is strictly tied as a conditional package with the KOSPI transfer, investors should interpret this as a procedural step rather than any deterioration in corporate Fundamental.

If the relocation is successfully approved by shareholders and granted by the Korea Exchange, it could have a potential positive impact on the company by attracting passive funds that track the KOSPI index and enhancing accessibility for global institutional investors. However, since other minority shareholders hold a significant 74.59% stake, the voting outcome at the EGM remains a key milestone to watch before the final relocation is confirmed.

📝 Editor’s Comment (by K-STOCK Editor)

The phrase ‘Delisting’ might have caused a brief panic, but rest assured, this is a positive maneuver to migrate to the main KOSPI board. Looking at the share structure, the largest shareholder and related parties hold 20.36%, while a separate 5% or greater shareholder owns 5.05%, and minority and other general investors account for a majority stake of 74.59%. Consequently, securing a smooth approval from this vast pool of general shareholders at the Daejeon EGM on December 8 will be the very first critical hurdle for Alteogen’s market relocation.

📢 Disclaimer and Source Information

Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) to List 6,700 New Shares Following Stock Option Exercise at KRW 8,065
Next Post: [Disclosure] Alteogen (196170) Sets November 21 as Record Date to Determine Voting Rights for Extraordinary General Meeting

Related Posts

[Disclosure] Alteogen (196170) to List 146,140 Additional Common Shares Following Stock Option Exercises Disclosures
[Disclosure] Alteogen(196170) to Receive KRW 21.9B Milestone Payment from MSD for ‘Keytruda SC’ European Approval Disclosures
[Disclosure] Alteogen (196170) Designated as Short-Selling Overheated Stock; Short-Selling Banned on May 15 Disclosures
[Disclosure] Alteogen(196170) Designated as Short Selling Overheated Stock… Short Selling Banned on Dec 8 Disclosures
[Disclosure] Alteogen (196170) to Receive USD 25M (KRW 35.05B) Milestone Payment from MSD Following U.S. FDA Approval of Keytruda SC Disclosures
[Disclosure] Alteogen(196170) Signs Exclusive License Agreement with GSK Subsidiary for ALT-B4 Valued up to KRW 420.0B Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hana Micron (067310) Lifted from Investment Warning Stock Status; Reclassified to Investment Caution on June 9 with Re-designation WarningJuly 8, 2026
  • [Discount Reversal via ADR Listing and Entry into an HBM-Led Super Cycle: SK hynix 000660]July 7, 2026
  • [Discount Narrowing via ADR Listing Momentum and Capital Allocation Diversification: SK Square 402340]July 7, 2026
  • Gaon Cable (000500): Structural Re-rating Driven by North American Infrastructure Expansion and AI Data Center Demand ShocksJuly 7, 2026
  • Hugel (145020): Passing the Trough with Q2 Earnings Surprise and Accelerated U.S. Direct Sales DeploymentJuly 7, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme